title: Severe herpes simplex virus hepatitis following autologous bone marrow transplantation: successful treatment with high dose intravenous acyclovir.
abstract: A 17-year-old male patient with T-cell type lymphoblastic lymphoma in complete remission underwent high dose chemotherapy (busulfan 16 mg/kg and cyclophosphamide 120 mg/kg) followed by autologous bone marrow transplantation (ABMT). The patient had been taking oral acyclovir (200 mg x 5) daily from seven days prior to the ABMT (day -7). On day +24, he complained of epigastralgia and general malaise, and the next day his GOT and GPT rose to 570 U/l and 397 U/l, respectively. Although he had no mucocutaneous lesions, hepatitis caused by a herpes virus was suspected, and high dose intravenous acyclovir (10 mg/kg x 3/day) was immediately started. His GOT, GPT and total bilirubin reached peaks of 2,870 U/l on day +26, 1,830 U/l on day +27 and 10.3 mg/dl on day +39, respectively, and rapidly improved thereafter. Serological analyses on IgG antibody titers to herpes simplex virus type 1 using an enzyme-linked immunosorbent assay revealed specific increases (454-fold before transplantation to 3,830-fold on day +46). Antiviral antibody titers to cytomegalovirus, varicella-zoster virus and Epstein-Barr virus showed no significant changes. The serologic markers of hepatitis B virus, hepatitis A virus and hepatitis C virus were all negative. The results indicate the patient's severe icteric hepatitis to have been caused by a reactivation of herpes simplex virus type 1 due to immunosuppression after high dose chemotherapy with ABMT. It is suggested that prompt commencement of high dose intravenous acyclovir is required to treat severe herpes simplex virus hepatitis affecting immunocompromised patients.
authors.affiliation: Hematology-Oncology and Medical Oncology Division, National Cancer Center Hospital, Tokyo.
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Takeyama
authors.forename: J
authors.initials: J
authors.lastname: Takayama
authors.forename: M
authors.initials: M
authors.lastname: Ohira
authors.forename: K
authors.initials: K
authors.lastname: Tobinai
authors.forename: M
authors.initials: M
authors.lastname: Shimoyama
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage*; D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy / Q000209:etiology*; D006561:Herpes Simplex / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000601:surgery; D014182:Transplantation, Autologous
chemical_list: D000212:Acyclovir